BridgeBio Pharma (BBIO) Net Margin (2019 - 2026)
BridgeBio Pharma (BBIO) posted Net Margin of 84.33% for Q1 2026, up 32.58% sequentially from 125.09% in Q4 2025, and up 5921.0% YoY from 1.4% in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Net Margin (2019 - 2026) Analysis & Trends
BridgeBio Pharma has reported Net Margin for 8 years, with the latest figure at 84.33% in Q1 2026.
- Quarterly Net Margin rose 5921.0% year-over-year to 84.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 124.41% (up 39983.0% YoY) and the FY2025 annual result came in at 144.39%, up 9705.0% from the prior year.
- Net Margin climbed to 84.33% in Q1 2026 per BBIO's latest filing, from 125.09% in the prior quarter.
- Over five years, Net Margin peaked at 13.36% in Q2 2022 and troughed at 40632.84% in Q3 2022.
- A 5-year average of 6198.18% and a median of 4326.55% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin slumped 3398032 bps in 2022, then jumped 3630629 bps in 2023.
- Over 5 years, Net Margin stood at 7357.81% in 2022, then sank by 31 bps to 9635.99% in 2023, then soared by 53 bps to 4506.12% in 2024, then soared by 97 bps to 125.09% in 2025, then jumped by 33 bps to 84.33% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 84.33%, 125.09%, and 151.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -62.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.47% |
| Mar 31, 2026 | -84.33% |
| Dec 31, 2025 | -125.09% |
| Sep 30, 2025 | -151.40% |
| Jun 30, 2025 | -164.52% |
| Mar 31, 2025 | -143.55% |
| Dec 31, 2024 | -4,506.12% |
| Sep 30, 2024 | -5,931.19% |
| Jun 30, 2024 | -3,388.19% |
| Mar 31, 2024 | -16.68% |
| Dec 31, 2023 | -9,635.99% |
| Sep 30, 2023 | -4,326.55% |
| Jun 30, 2023 | -9,622.12% |
| Mar 31, 2023 | -7,675.58% |
| Dec 31, 2022 | -7,357.81% |
| Sep 30, 2022 | -40,632.84% |
| Jun 30, 2022 | -13.36% |
| Mar 31, 2022 | -11,593.68% |
| Dec 31, 2021 | -1,471.77% |
| Sep 30, 2021 | -6,652.52% |